Literature DB >> 25624151

Factors affecting ¹⁸F FDOPA standardized uptake value in patients with primary brain tumors after treatment.

Agostino Chiaravalloti1, Alessandro Fiorentini2, Veronica Villani3, Carmine Carapella4, Andrea Pace3, Barbara Di Pietro2, Carmen Di Russo2, Barbara Palumbo5, Roberto Floris2, Orazio Schillaci6.   

Abstract

AIM: To investigate the factors affecting (18)F FDOPA uptake in patients with primary brain tumors (PBT) after treatment.
MATERIALS AND METHODS: 97 patients with PBT (6 were grade I, 40 were grade II, 29 were grade III and 22 were grade IV) underwent (18)F FDOPA positron emission tomography/computed tomography (PET/CT) after treatment. Intervals from surgery, chemotherapy (CHT) and radiotherapy (RT) were 41.48 (±42.27), 16.04 (±29.08) and 28.62 (±34.49) months respectively.
RESULTS: (18)F FDOPA uptake in the site of recurrence was not related to the interval from surgery and CHT while a significant relationship has been found with the interval from RT and tumor grade.
CONCLUSIONS: The results of our study show that the interval from RT and the grade of PBT should be considered carefully when evaluating brain PET/CT scans since these factors could directly affect (18)F FDOPA uptake.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F FDOPA; Chemotherapy; Primary brain tumors; Radiotherapy; SUV; Surgery

Mesh:

Substances:

Year:  2015        PMID: 25624151     DOI: 10.1016/j.nucmedbio.2015.01.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.

Authors:  Ryan S Youland; Deanna H Pafundi; Debra H Brinkmann; Val J Lowe; Jonathan M Morris; Bradley J Kemp; Christopher H Hunt; Caterina Giannini; Ian F Parney; Nadia N Laack
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

2.  Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting.

Authors:  Mariam Aboian; Ramon Barajas; Julia Shatalov; Vahid Ravanfar; Emma Bahroos; Elizabeth Tong; Jennie W Taylor; N Oberheim Bush; Patricia Sneed; Youngho Seo; Soonmee Cha; Miguel Hernandez-Pampaloni
Journal:  Neurooncol Pract       Date:  2020-10-14

3.  [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression.

Authors:  Bérengère Dadone-Montaudié; Damien Ambrosetti; Maxime Dufour; Jacques Darcourt; Fabien Almairac; John Coyne; Thierry Virolle; Olivier Humbert; Fanny Burel-Vandenbos
Journal:  PLoS One       Date:  2017-09-22       Impact factor: 3.240

4.  Subependymal Spread of Glioblastoma Multiforme in Positron Emission Tomography/Computed Tomography.

Authors:  Agostino Chiaravalloti; Orazio Schillaci Pasqualina Sannino
Journal:  Indian J Nucl Med       Date:  2017 Jan-Mar

5.  Effects of Photons Irradiation on 18F-FET and 18F-DOPA Uptake by T98G Glioblastoma Cells.

Authors:  Francesca Pasi; Marco G Persico; Manuela Marenco; Martina Vigorito; Angelica Facoetti; Marina Hodolic; Rosanna Nano; Giorgio Cavenaghi; Lorenzo Lodola; Carlo Aprile
Journal:  Front Neurosci       Date:  2020-11-13       Impact factor: 4.677

6.  MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [18F]FDOPA Uptake in Primary Brain Tumors.

Authors:  Andrea Cimini; Agostino Chiaravalloti; Maria Ricci; Veronica Villani; Gianluca Vanni; Orazio Schillaci
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

7.  Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature.

Authors:  François Somme; Laura Bender; Izzie Jacques Namer; Georges Noël; Caroline Bund
Journal:  Cancer Imaging       Date:  2020-10-06       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.